|Humoral immunoreactivity to gliadin and to tissue transglutaminase is present in some patients with multiple myeloma.|
|Jump to Full Text|
|PMID: 18507842 Owner: NLM Status: MEDLINE|
|BACKGROUND: Multiple myeloma (MM) is a clonal B-cell disorder with many immunological disturbances. The aim of this work was to assess whether some of food antigens contribute to the imbalance of immune response by screening the sera of MM patients for their immunoreactivity to food constituent gliadin, to tissue transglutaminase-2 (tTG-2) and to Ro/SSA antigen.Sera from 61 patients with MM in various stages of disease, before, or after some cycles of conventional therapy were analyzed by commercial Binding Site ELISA tests. The control group consisted of 50 healthy volunteers. Statistical analysis of data obtained was performed by Mann Whitney Test.
RESULTS: The higher serum IgA immunoreactivity to gliadin was found in 14/56 patients and in one of control people. The enhanced serum IgG immunoreactivity to gliadin was found in only two of tested patients and in two controls. The enhanced IgA immunoreactivity to tTG-2 was found in 10/49 patients' sera, while 4/45 patients had higher serum IgG immunoreactivity. The enhanced serum IgG immunoreactivity to RoSSA antigen was found in 9/47 analyzed MM patients' sera. Statistical analysis of data obtained revealed that only the levels of anti-tTG-2 IgA immunoreactivity in patients with MM were significantly higher than these obtained in healthy controls (P < 0.02)
CONCLUSION: Data obtained showed the existence of the enhanced serum immunoreactivity to gliadin, tTG-2 and Ro/SSA antigens in some patients with MM. These at least partially could contribute to the immunological imbalance frequently found in this disease.
|Zorica Juranic; Jelena Radic; Aleksandra Konic-Ristic; Svetislav Jelic; Biljana Mihaljevic; Ivan Stankovic; Suzana Matkovic; Irina Besu; Dusica Gavrilović|
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2008-05-28|
|Title: BMC immunology Volume: 9 ISSN: 1471-2172 ISO Abbreviation: BMC Immunol. Publication Date: 2008|
|Created Date: 2008-06-09 Completed Date: 2009-02-23 Revised Date: 2013-06-05|
Medline Journal Info:
|Nlm Unique ID: 100966980 Medline TA: BMC Immunol Country: England|
|Languages: eng Pagination: 22 Citation Subset: IM|
|Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
Antibodies / blood, immunology
Enzyme-Linked Immunosorbent Assay
GTP-Binding Proteins / immunology*
Gliadin / immunology*
Immunoglobulin A / blood, immunology
Immunoglobulin G / blood, immunology
Multiple Myeloma / blood, immunology*, pathology
Ribonucleoproteins / immunology*
Statistics as Topic
Transglutaminases / immunology*
|0/Antibodies; 0/Immunoglobulin A; 0/Immunoglobulin G; 0/Ribonucleoproteins; 0/SS-A antigen; 9007-90-3/Gliadin; EC 2.3.2.-/transglutaminase 2; EC 126.96.36.199/Transglutaminases; EC 3.6.1.-/GTP-Binding Proteins|
Journal ID (nlm-ta): BMC Immunol
Publisher: BioMed Central
Copyright ? 2008 Juranic et al; licensee BioMed Central Ltd.
open-access: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received Day: 26 Month: 3 Year: 2008
Accepted Day: 28 Month: 5 Year: 2008
collection publication date: Year: 2008
Electronic publication date: Day: 28 Month: 5 Year: 2008
Volume: 9First Page: 22 Last Page: 22
Publisher Id: 1471-2172-9-22
PubMed Id: 18507842
|Humoral immunoreactivity to gliadin and to tissue transglutaminase is present in some patients with multiple myeloma|
|Zorica Juranic1||Email: firstname.lastname@example.org|
|Jelena Radic1||Email: email@example.com|
|Aleksandra Konic-Ristic2||Email: firstname.lastname@example.org|
|Svetislav Jelic1||Email: email@example.com|
|Biljana Mihaljevic3||Email: firstname.lastname@example.org|
|Ivan Stankovic2||Email: email@example.com|
|Suzana Matkovic1||Email: firstname.lastname@example.org|
|Irina Besu1||Email: email@example.com|
|Du?ica Gavrilovi?1||Email: firstname.lastname@example.org|
1Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia
2Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
3School of Medicine, University of Belgrade, Belgrade, Serbia
Multiple myeloma (MM) is a clonal B-cell disorder which diagnosis comprise the examination of bone marrow for plasma cell infiltration, detection and quantification of monoclonal protein "M" component in the serum or urine, and evidence of end-organ damage (hypercalcemia, renal insufficiency, anemia or bone lesions). Many of the laboratory parameters contribute to myeloma diagnosis due to plenty of immunological disturbances . It was shown that the antibodies contained in M component have various specificity to: some proteins, double-stranded DNA, several antibiotics , and sometimes to gliadin (and/or calreticulin?) .
As the enhanced levels of the serum antibodies to gliadin are found in patients with celiac disease, as well as of antibodies to transglutaminase-2 (TTG-2) [4,5], to calreticulin [6,7] and Ro/SSA antigen , the aim of this work was the screening of MM patients' sera for their immunoreactivity to food constituent gliadin, and to autoantigens: tissue transglutaminase-2 (tTG-2) and Ro/SSA antigen, in order to assess whether immunoreactivity to mentioned antigens at least partially contributes to the immunological imbalance in multiple myeloma.
Sera from 61 patients with MM in various stages of disease, before or after some cycles of conventional therapy, were analyzed for immunity to gliadin, tissue TTG-2, and Ro/SSA antigen. Determination of serum IgA and IgG immunoreactivity to gliadin (IU/ml), to tTG-2 (IU/ml), or to Ro/SSA (IU/ml), was done by diagnostic, commercial ELISA (Binding Site) tests. Briefly, 100 ?l of diluted (1:100) human sera, commercial controls and calibrators were dispensed in appropriate wells of the plates provided in the kit. During the first incubation, autoantibodies recognizing the antigen bind to it and all unbound proteins were removed by washings. After that, purified peroxidase labeled rabbit anti human IgA or IgG conjugate (100 ?l) which binds to the captured human autoantibodies was added, and the excess unbound conjugate is removed by washings. The conjugate was treated with TMB (3,3,5,5-tetramethylbenzidine). The reaction was stopped by the addition of phosphoric acid. The concentration of autoantibodies was measured on ELISA reader at 450 nm. Cut offs for each test was evaluated as the mean X+2 SD.
The control group consisted of 50 healthy volunteers (age range was 27?58 years, 26 were female).
Statistical analysis of data obtained was performed by Mann Whitney Test.
Experimental research that is reported in the manuscript has been performed with the approval of the ethics committee of Institute of Oncology and Radiology of Serbia.
Cut off values of anti-gliadin reactivity obtained analyzing 50 healthy sera were 3.46 IU/ml for IgA and 5.83 IU/ml for IgG.
The elevated serum IgA immunoreactivity to gliadin was found in 14/56 patients and in one of controls. From these patients, 4 were with IgA myeloma and 4 were with IgG myeloma, while 6 were without M component in their sera.
Statistical analysis of data obtained revealed that the level of anti-gliadin IgA immunoreactivity for patients with MM was not significantly differ than that for controls (P = 0.052).
Surprisingly, the elevated IgG immunoreactivity to gliadin was found only in two of tested MM patients sera and in two of control people (Fig 1.) and both patients were with IgG myeloma.
Cut off values of anti-tTg reactivity obtained analyzing 50 healthy sera were 1.86 IU/ml for IgA and 6.17 IU/ml for IgG.
As seen on Fig. 2.a. higher than cut off of IgA immunoreactivity to tTG was found in 10/49 patients and 2 of controls. From 10 anti-tTg IgA positive patients 4 were with IgA and 4 were with IgG myeloma, while 2 were without M component in their sera. Statistical analysis of data obtained revealed that the level of anti-tTG-2 IgA immunoreactivity in patients with myeloma was significantly higher than that obtained in healthy controls (P < 0.02).
Sera from 4/45 patients and 3 controls had higher than cut off value for IgG immunoreactivity (Fig. 2.b). All 4 anti-tTg IgG positive patients were with IgG MM.
Cut off values of anti-Ro/SSA IgG reactivity obtained analyzing 50 healthy sera was 3.59 IU/ml. The enhanced IgG immunoreactivity to RoSS? antigen found in this work in 9/47 analyzed MM patients' sera (Fig. 3). These anti-RoSS? IgG positive patients were: 2 with IgA, 5 with IgG, and 2 without M component.
In this work, the immunoreactivity to one of the food constituents is found in some MM patients. It is manifested through the enhanced levels of serum IgA immunoreactivity to gliadin. Data obtained by ELISA tests indicate that especially anti-gliadin, IgA immunity is developed in patients with MM. It seems that the elevated immunoreactivities to gliadin could not be the consequence of overproduction of immmunoglobulins from M component, because the enhanced antigliadin IgA immunoreactivity was found in the serum of some of MM patients without M component as well as in patients with IgG myeloma too. It is also possible that in some patients serum antigliadin immunoreactivities could be hidden in immune complexes in circulation (CIC) and in these cases this reactivity could not be revealed by ELISA test. One of the solutions for this problem could be the electrophoresis of serum proteins performed in the alkaline conditions pH = 8.6 i.e., in conditions which enables dissociation of antibodies from antigen in CIC [9,10]; these antibodies physically separated from the gliadin by electrophoresis could then again react with gliadin (0.2%, or 0.4% in 0.5% SDS) in the test for immunofixation .
It must be mentioned that only the level of anti tTG-2 IgA immunoreactivity in patients with myeloma was significantly higher than these obtained in healthy controls. Besides, our results show that autoimmune determinants as the enhanced immunity to tTG-2, and to Ro/SSA antigen, which are present in patients with gluten intolerance [4,5] and autoimmune diseases  respectively, are present in some patients with MM, too.
Immunoreactivity to some of these antigens was also found in few of healthy controls, indicating that the immunoreactivities to tTG or to Ro/SSA antigens, or to gliadin are not strictly specific for MM, but that they are only one part of the complex immunological disturbances found in this disease. Findings from this work are in accordance with the previously published reports [11-14] pointing to the partial immunological similarity between MM and celiac disease.
This work indicates that gliadin as food antigen could at least partially contribute to the plethora of immunological disturbances in some patients with MM. Due to the aminoacid sequence equality or high homology between ?-gliadin and ?-gliadin and C albicans?hyphal wall protein 1 (HWP1), and with calreticulin, it is also possible that the determined immunoreactivity with gliadin is in part the consequence of the cross reactivity with mentioned proteins .
Data from this work showed the existence of the enhanced serum immunoreactivity to gliadin, tTG-2 and Ro/SSA antigens in some patients with MM and set up the question whether MM is also on the list of malignant diseases which are associated with immunological aspect of gluten intolerance [16-19]. They call for the additional research to elucidate the clinical importance of both: the elevated humoral immunity to food antigens and to some autoantigens in patients with MM.
ZJ designed the study, interpreted the data and wrote the manuscript. AK?R and IB have done the ELISA blood testing, collected the data, and organized the database, while DG performed the statistical analysis. SJ, SM and BM enrolled the patients with myeloma, revised critically the manuscript and added important points to the discussion, JR have done determination of the type of heavy and light immunoglobulin chains presented in the M component in the serum, by immunofixation. IS helped with ELISA serum testing. All authors approved the final draft of the manuscript.
This work was financed by Ministry of Science and Environmental Protection of Serbia grant numbers 145006 and 145055. Authors express their gratitude to Ljiljana Vuckovic-Dekic for editing the manuscript.
|Dispenzieri A,Kyle RA. Multiple myeloma: clinical features and indications for therapyBest Pract Res Clin Haematol 2005;18:553–568. [pmid: 16026737] [doi: 10.1016/j.beha.2005.01.008]|
|Merlini G,Farhangi M,Osserman EF. Monoclonal immunoglobulins with antibody activity in myeloma, macroglobulinemia and related plasma cell dyscrasiasSemin Oncol 1986;13:350–365. [pmid: 3094150]|
|Juranic Z,Radic J,Konic-Ristic A,Jelic S,Mihaljevic B,Besu I. Antibodies contained in "M" component of some patients with multiple myeloma are directed to food antigens?Leuk Res :1585–1586. 2006; Mar 3 [pmid: 16516966]|
|Troncone R,Maurano F,Rossi M,Micillo M,Greco L,Auricchio R,Salerno G,Salvatore F,Sacchetti L. IgA antibodies to tissue transglutaminase: An effective diagnostic test for celiac diseaseJ Pediatr 1999;134:166–171. [pmid: 9931524] [doi: 10.1016/S0022-3476(99)70410-5]|
|Tiberti C,Bonamico M,Dotta F,Verrienti A,Di Tola M,Liu E,Ferri M,Nenna R,Picarelli A,Eisenbarth GS. Evidence of a selective epitope loss of anti-transglutaminase immunoreactivity in gluten-free diet celiac sera: A new tool to distinguish disease-specific immunoreactivitiesClin Immunol. Available online 23 June 2006|
|Sanchez DL,Tuckova L,Sebo P,Michalak M,Whelan A,Sterzl I,Jel?nkova L,Havrdova E,Imramovska M,Benes Z,Krupickova S,Tlaskalova-Hogenova H. Occurrence of IgA and IgG Autoantibodies to calreticulin in Coeliac Disease and Various Autoimmune DiseasesJ Autoimmun 2000;15:441–449. [pmid: 11090243] [doi: 10.1006/jaut.2000.0452]|
|Malhotra R. Collectin receptor (C1q receptor): structure and functionBehring Inst Mitt 1993;93:254–61. [pmid: 8172575]|
|Bonaci-Nikolic B,Andrejevic S,Radlovic N,Davidovic I,Sofronic L,Spuran M,Micev M,Nikolic MM. Serological and clinical comparison of children and adults with anti-endomysial antibodiesJ Clin Immunol 2007;27:163–71. Epub 2007 Jan 23. [pmid: 17243009] [doi: 10.1007/s10875-006-9062-y]|
|Schutzer SE,Coyle PK,Reid P,Holland B. Borrelia burgdorferi-specific immune complexes in acute Lyme diseaseJAMA 2000;284:695–696. [pmid: 10927775] [doi: 10.1001/jama.284.6.695]|
|Brunner M,Sigal LH. Use of serum immune complexes in a new test that accurately confirms early Lyme disease and active infection with Borrelia burgdorferiJ Clin Microbiol 2001:3213–3221. [pmid: 11526153] [doi: 10.1128/JCM.39.9.3213-3221.2001]|
|Street ME,Volta C,Ziveri MA,Zanacca C,Banchini G,Viani I,Rossi M,Virdis R,Bernasconi S. Changes and relationships of IGFS and IGFBPS and cytokines in coeliac disease at diagnosis and on gluten-free dietClin Endocrinol (Oxf). 2007 Aug 6|
|Ebert EC. IL-15 converts human intestinal intraepithelial lymphocytes to CD94 producers of IFN-gamma and IL-10, the latter promoting Fas ligand-mediated cytotoxicityImmunology 2005;115:118–26. [pmid: 15819704] [doi: 10.1111/j.1365-2567.2005.02132.x]|
|Sfiridaki A,Miyakis S,Tsirakis G,Alegakis A,Passam AM,Kandidaki E,Margioris AN,Alexandrakis MG. Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone diseaseClin Chem Lab Med 2005;43:934–8. [pmid: 16176173] [doi: 10.1515/CCLM.2005.160]|
|Pappa C,Miyakis S,Tsirakis G,Sfiridaki A,Alegakis A,Kafousi M,Stathopoulos EN,Alexandrakis MG. Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myelomaCytokine 2007;37:171–5. [pmid: 17446083] [doi: 10.1016/j.cyto.2007.02.022]|
|Nieuwenhuizen WF,Pieters RH,Knippels LM,Jansen MC,Koppelman SJ. Is Candida albicans a trigger in the onset of coeliac disease?Lancet 361:2152–4. 2003 Jun 21 [pmid: 12826451] [doi: 10.1016/S0140-6736(03)13695-1]|
|Cellier C,Delabesse E,Helmer C,Patey N,Matuchansky C,Jabri B,Macintyre E,Cerf-Bensussan N,Brousse N. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphomaLancet 2000;356:203–208. [pmid: 10963198] [doi: 10.1016/S0140-6736(00)02481-8]|
|Catassi C,Fabiani E,Corrao G,Barbato M,De Renzo A,Carella AM,Gabrielli A,Leoni P,Carroccio A,Baldassarre M,Bertolani P,Caramaschi P,Sozzi M,Guariso G,Volta U,Corazza GR. Risk of non-Hodgkin lymphoma in coeliac diseaseJAMA 2000;287:1413–1419. [pmid: 11903028] [doi: 10.1001/jama.287.11.1413]|
|Van Overbeke L,Ectors N,Tack J. What is the role of celiac disease in enteropathy-type intestinal lymphoma? A retrospective study of nine casesActa Gastroenterol Belg 2005;68:419–423. [pmid: 16432993]|
|Brousse N,Meijer JW. Malignant complications of coeliac diseaseBest Pract Res Clin Gastroenterol 2005;19:401–412. [pmid: 15925845] [doi: 10.1016/j.bpg.2005.02.002]|
|Silano M,Volta U,Mecchia AM,Dessi M,Di Benedetto R,De Vincenzi M. Collaborating centers of the Italian registry of the complications of coeliac disease. Delayed diagnosis of coeliac disease increases cancer riskBMC Gastroenterol 7:8. 2007 Mar 9 [pmid: 17349035] [doi: 10.1186/1471-230X-7-8]|
Previous Document: SOCS3 inhibiting migration of A549 cells correlates with PYK2 signaling in vitro.
Next Document: Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and o...